US FDA Approves Controversial Rare Disease Drug Despite Data Reviewers’ Objections

In a contentious decision announced in September 2025, the U.S. Food and Drug Administration (FDA) approved a costly drug designed to treat a rare genetic disorder, despite internal data reviewers’ findings that the treatment was no more effective than a placebo. The decision has sparked significant debate among medical experts, patient advocates, and regulatory observers about the agency’s approval standards for rare disease therapies.

The drug, developed by Stealth BioTherapeutics, aims to address Barth syndrome, a rare mitochondrial disease characterized by muscle weakness and severe health complications affecting both children and adults. The FDA’s approval followed years of back-and-forth with the company; the agency initially declined to consider the drug for full approval in 2021 and rejected the application as recently as May 2025. However, an FDA advisory committee later endorsed the drug’s effectiveness based on limited muscle strength improvements considered “reasonably likely” to translate to patient benefit.​

Key Findings and Developments

Internal FDA documents obtained through a Reuters review reveal that the clinical review team leader strongly advised against approving the drug, citing insufficient evidence to prove its efficacy beyond placebo effects. The data reviewers acknowledged the drug’s safety profile but argued that the clinical trial results failed to demonstrate “substantial evidence” of effectiveness required for traditional or accelerated approval pathways.​

Despite these concerns, the decision was influenced by external pressures, including a letter signed by over 80 physicians and patient advocates calling on FDA Commissioner Martin Makary to expedite approval or provide a quick review. Families affected by the disease, like the Archibald family who have three children with the condition, also pushed for rapid access to the treatment, emphasizing the dire unmet need for therapeutic options.​

Expert Perspectives

Dr. Steven Hirsch, a mitochondrial disease researcher unaffiliated with the drug’s development, commented on the approval’s implications: “Barth syndrome is a rare and devastating condition with limited treatment options. While the drug’s approval represents hope, the lack of robust efficacy data means we must be cautious in interpreting what benefits patients might realistically expect”.​

Similarly, Dr. Jessica Lopez, a clinical pharmacologist, highlighted the challenges in rare disease drug approval: “With small patient populations, clinical trials can face significant limitations, leading to reliance on surrogate endpoints or limited data. Balancing expedited access with rigorous evidence is tricky, but essential to maintain public trust”.​

Context and Background

Rare diseases collectively affect millions worldwide, but individually, conditions like Barth syndrome affect only a small number of patients. This scarcity complicates clinical research, making traditional large-scale trials impractical. In response, the FDA has developed regulatory mechanisms such as accelerated approval and orphan drug designations to facilitate the development of therapies for rare diseases, sometimes with less stringent evidence requirements while still ensuring safety.​

However, this case accentuates ongoing controversies regarding the FDA’s leniency and potential conflicts of interest in rare disease drug approvals. Critics argue that industry pressure and political lobbying can push the FDA toward faster approvals that may not fully prove therapeutic benefit, while others emphasize the urgent need for treatments where none existed.​

Public Health Implications

The approval enables patients with Barth syndrome to access the drug under the FDA’s regulatory framework. However, the drug’s high cost—estimated at $800,000 annually—raises concerns about affordability and equitable access, particularly as its clinical benefits remain uncertain. Healthcare providers must therefore weigh these factors carefully when considering treatment, balancing hope for improved outcomes with the potential economic and medical burdens.​

From a public health perspective, this decision highlights the tension between fast-tracking treatments for rare diseases and maintaining rigorous standards that ensure efficacy and value. It also underscores the importance of ongoing post-market surveillance and real-world evidence collection to clarify long-term benefits and safety.

Limitations and Counterarguments

The FDA’s approval decision is not without its limitations. The primary evidence supporting the drug’s efficacy centers on muscle strength improvements deemed surrogate markers rather than direct patient-centered outcomes. Additionally, small sample sizes and potential biases in the submitted data introduce uncertainties. Some agency reviewers have expressed concerns about setting precedents for approvals based on placebo-like effectiveness, which could influence future rare disease drug assessments.​

Opponents of the approval decision warn against overreliance on expedited pathways that may compromise scientific rigor. Still, patient advocates argue that for rare diseases with no alternatives, any potential treatment should be made available, especially given the typically fatal or severely debilitating nature of these conditions.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References